Hair Loss on Ozempic and GLP-1 Genetic Explanation

Recent scientific research published on September 3, 2026, in the Journal of Investigative Dermatology reveals that hair loss experienced by individuals taking popular GLP-1 receptor agonists like Ozempic, Wegovy, and Zepbound may not be solely caused by rapid weight loss. Researchers at NYU Langone Health discovered a direct genetic link between higher activity of the GLP1R gene and an increased risk of androgenetic alopecia, commonly known as male-pattern baldness. The study's senior investigator, Dr. Lynn Petukhova, and her team highlight that genetically susceptible men possessing higher levels of GLP-1 receptor proteins face an additional 7 percent risk of developing pattern hair loss. This biological mechanism suggests that the GLP-1 pathway itself interacts with hair follicle growth, challenging the long-held assumption that temporary shedding is exclusively a byproduct of sudden dietary changes or rapid weight reduction. By employing a two-sample Mendelian randomization approach utilizing large public databases including eQTLGen and Complex Traits Genetics, the researchers controlled for confounding factors such as hypertension, insulin resistance, and lower testosterone levels. None of these alternative health conditions accounted for the established statistical association, reinforcing the hypothesis of a dedicated biological connection between GLP-1 receptor activity and hair thinning. While the current findings are statistically limited to male populations due to broader historical research data and predominantly White cohorts, future clinical explorations may lead to targeted pre-treatment screenings and combinatorial preventative therapies like minoxidil. As prescription rates for weight loss medications triple since 2020, understanding these underlying genetic risk factors will help clinicians better advise vulnerable patients before beginning long-term pharmacological treatment.